Itraconazole Therapy In Bronchiectasis With Airway Mold

Inclusion Criteria: * Age ≥18 years seen at Mycobacterial and Bronchiectasis Clinic (MMBC) in Rochester * Diagnosis of bronchiectasis confirmed by MMBC provider and chest CT * Within the last 3 months - culture growth of a mold in high quantity ('many') or culture growth of at least two distinct mold species in any quantity * Not actively on antimicrobial therapy AND no current plan to initiate antimicrobial therapy at the time of enrollment, as determined by treating provider * Ability to produce spontaneous sputum at Visit 1. Exclusion Criteria: * Known diagnosis of allergic bronchopulmonary aspergillosis or invasive fungal disease * Use of the following medications: rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, dofetilide, quinidine, dronedarone, simvastatin, lovastatin, certain immunosuppressants (tacrolimus, cyclosporine, sirolimus, everolimus) and anticoagulants (rivaroxaban, apixaban, edoxaban, warfarin). * Abnormal baseline liver function tests (ALT, AST, alkaline phosphatase, or bilirubin \> upper limit of normal) * Prolonged QTc interval on baseline ECG (\>460 ms in females or \>450 ms in males) * History of congestive heart failure (black box warning), known cardiomyopathy, or arrhythmias * Pregnancy or lactation * Known hypersensitivity or contraindication to azole antifungal therapy * Prior use of systemic antifungals within the past 3 months